A case study in differing approaches to reimbursement approval in Europe and the US.
Does Real World Evidence Matter in Health Technology Assessments?
pharmaphorum recently published an article written by our Founder and CEO Yin Ho and Associate Data Analyst Daniel Liden: "Sovaldi and the Politics of High Priced Drugs: Are We Asking the Right Questions?"
Context Matters is in the news again! This time with our analysis on value assessments by UK's National Institute for Health and Care Excellence (NICE) for cancer medicines.
Context Matters data cited in the Wall Street Journal! Ed Silverman recently spoke with PhRMA's Randy Burkholder, who noted that between 2007 and 2013, cancer medicines were more than three times as likely to receive unfavorable recommendations from UK agency NICE, as compared with other drugs.
pharmaphorum recently published an article written by our Founder and CEO Yin Ho and Research Analyst Daniel Sanchez: "When Measuring European Regulatory Approval, the Timestamp Matters." The article looks at cycle times in regulatory decisions and how they are being measured in the US and Europe. A cycle time measures the time from the date of submission, through date of approval. We noticed that some of the analyses involving the European Medicines Agency (EMA)’s cycle time used an inappropriate endpoint, resulting in cycle times that looked two months shorter than they actually are.
PharmaPhorum recently published an article written by our Founder and CEO Yin Ho and Associate Director of Data and Analytics Rachel Jao, "Overcoming the Market Access Hurdle through Better Planning of Clinical Trials." The article points out that though regulatory approval is still a key step in getting a drug to market, it no longer guarantees market access. The authors discuss how clinical-trial design and the implications on reimbursement can help companies make better use of their resources and expedite the path to a successful drug launch.
Fierce Biotech recently featured Context Matters in an e-book "Picking Winners: Data Mining for Drug Discovery". Our founder and CEO Yin Ho discusses how biotech and pharma companies are starting to understand the importance of reimbursement data and the insights that can be learned from following these patterns early in the drug development process.
Drug Discovery News recently did a feature story, "Keeping the Fast Lane Open" that used our research and thinking from our three-part series "Life in the Fast Track." Since there has been a lot of discussion recently about the FDA’s new “Breakthrough Therapy” designation, we thought it would be interesting to look at some previous FDA fast lanes to see if they have actually made a difference in the speed and process of bringing drugs to market.
The trending topic of data transparency has been making news recently. The European Federation of Pharmaceutical Industries (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) have agreed to make their clinical trial data more readily available for public inquiry. Our Founder and CEO, Yin Ho, was asked to comment on this recently, in a Specialty Pharmacy Times piece, "Pharmaceutical Trade Groups Endorse Data Sharing, with Conditions."
Our Founder and CEO Yin Ho was recently featured in a MedCity News piece asking "What did you learn from your biggest critic?"
FierceBiotechIT recently wrote about our analysis of online data, researched by the team here at Context Matters in collaboration with Pfizer, that found only 7.4% (47 trials) of 650 Phase 3 and Phase 2/3 clinical trials for diabetes treatments included patient-reported outcomes.
From Drug Development through Reimbursement, Context Matters, Inc. is providing Pharmaceutical Companies with the Large Sets of Data needed to Assess Risk and Reward You can read the full article on ceocfointereviews.com
MedCity News recently did a piece about 40 women to watch and included our founder and CEO Yin Ho on the list.
Managed Care recently did an article about our study on the use of the terms "Effectiveness" and "Efficacy" and how they are often used interchangeably or even misused.
Pharmalot did a piece recently on our study about the use of the terms "Efficacy" and "Effectiveness" when making reimbursement decisions. Our study focused on the differences in the terms and how they are often used interchangably in the industry.
Check out this great article about our flagship product the Reimbursement Risk Tracker on MedCity News. The article focused on our tool and how it's been designed to help drug developers save time and money by easily getting information from disparate sources.
The Reimbursement Risk Tracker enables Context Matters clients to drill down into a reimbursement context to understand restrictions on reimbursement, clinical and economic outcome thresholds and the disease prevalence and indications for 35 disease conditions.
Health Tech Zone did a recent article on our study comparing the value of clinical outcomes as compared to Health Technology Assessments (HTAs). Our study focused on the differences between the two and how they affect reimbursement decisions.
Our recent global analysis of product evaluations for Health Technology Assessments – which are often influential in decision making for approving and/or providing reimbursement for pharmaceuticals and other medical technology – found that the use of patient-reported outcomes (PROs) increased between 2005 and 2011.